Efficacy of Tocilizumab in the Treatment of Systemic Onset Juvenile Idiopathic Arthritis

Background: Systemic JIA (sJIA) is the most severe sub type of JIA with limited
treatment option and responsible for most of the disability and morbidity in JIA.

Download PDF